Q1 Earnings Forecast for TNYA Issued By Lifesci Capital

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) – Analysts at Lifesci Capital issued their Q1 2025 earnings estimates for shares of Tenaya Therapeutics in a research report issued on Tuesday, March 11th. Lifesci Capital analyst C. Jubinville expects that the company will post earnings of ($0.15) per share for the quarter. The consensus estimate for Tenaya Therapeutics’ current full-year earnings is ($1.35) per share. Lifesci Capital also issued estimates for Tenaya Therapeutics’ Q2 2025 earnings at ($0.18) EPS, Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.22) EPS and FY2025 earnings at ($0.73) EPS.

Tenaya Therapeutics (NASDAQ:TNYA) last announced its earnings results on Monday, March 17th. The company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.32) by $0.04.

Several other research firms have also issued reports on TNYA. Chardan Capital lowered their price target on shares of Tenaya Therapeutics from $18.00 to $9.00 and set a “buy” rating for the company in a report on Wednesday. Morgan Stanley lowered their target price on shares of Tenaya Therapeutics from $15.00 to $5.00 and set an “overweight” rating for the company in a research note on Wednesday. Finally, HC Wainwright cut their price target on shares of Tenaya Therapeutics from $18.00 to $5.00 and set a “buy” rating on the stock in a research report on Tuesday. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $8.75.

Tenaya Therapeutics Price Performance

Tenaya Therapeutics stock opened at $0.60 on Wednesday. The stock’s 50 day moving average is $1.09 and its 200 day moving average is $1.84. Tenaya Therapeutics has a one year low of $0.39 and a one year high of $5.55. The firm has a market cap of $47.56 million, a P/E ratio of -0.42 and a beta of 2.83.

Hedge Funds Weigh In On Tenaya Therapeutics

Institutional investors have recently made changes to their positions in the stock. Synovus Financial Corp acquired a new stake in shares of Tenaya Therapeutics in the 3rd quarter valued at about $28,000. Woodline Partners LP acquired a new stake in Tenaya Therapeutics in the fourth quarter valued at approximately $28,000. Commerce Bank acquired a new stake in Tenaya Therapeutics in the fourth quarter valued at approximately $29,000. Mariner LLC bought a new stake in shares of Tenaya Therapeutics during the fourth quarter valued at approximately $30,000. Finally, Ground Swell Capital LLC bought a new position in shares of Tenaya Therapeutics in the 4th quarter worth $32,000. Institutional investors and hedge funds own 90.54% of the company’s stock.

Insider Transactions at Tenaya Therapeutics

In related news, major shareholder Group Gp Lp Column III bought 35,714,284 shares of the business’s stock in a transaction that occurred on Wednesday, March 5th. The shares were acquired at an average cost of $0.70 per share, with a total value of $24,999,998.80. Following the completion of the purchase, the insider now directly owns 49,313,559 shares in the company, valued at $34,519,491.30. The trade was a 262.62 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders sold a total of 19,621 shares of company stock valued at $10,595 in the last quarter. 32.76% of the stock is currently owned by company insiders.

Tenaya Therapeutics Company Profile

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.